TVRD - Pendapatan operasional sadurunge ngurangi amortisasi caratherapeutics.com

Tandha merek Cara Therapeutics, Inc. (TVRD)

Due to the failure of key developments, Cara Therapeutics Inc (TVRD) has scaled back its programs and is minimizing expenses. High barriers to entry are ensured by patents for renal itch therapy and strict FDA control. The absence of stable revenue leads to constant cash burn. The change in EBITDA demonstrates a market compromise regarding the ability to generate cash, where 0.00 reflects the latest value of the metric.

caratherapeutics.com (TVRD) - Bathi sadurunge mbayar bunga, pajak, lan amortisasi saka 23.11.2025 nganti 17.11.2026

caratherapeutics.com - rincian analitis lan metrik utama (TVRD)

Ringkesan analitik perusahaan:TVRD - Cara Therapeutics Inc
Produk asil prodhuksi Cara Therapeutics Inc

As a portfolio manager, I view this indicator as a real cash flow filter that excludes non-cash charges and accounting adjustments. By analyzing the EBITDA as of the current date, an investor assesses the ability of Cara Therapeutics Inc (TVRD) to monetize its scientific reputation in nephrology, separating sustainable operational efficiency from one-time financial anomalies in the drug development process.